CD74

CD74 (HLA class II histocompatibility antigen gamma chain; HLA-DR antigens-associated invariant chain) 是一种 II 型跨膜蛋白。CD74 参与 MHC II 类肽复合物的形成和运输,以产生 CD4+ T 细胞反应。细胞表面 CD74 在许多细胞类型上充当细胞因子巨噬细胞迁移抑制因子 (MIF) 的受体。在免疫细胞中,MIF 与 CD74 结合会诱导信号级联,从而调节细胞增殖和存活。CD74 与肿瘤进展和转移有关。 CD74 表达被认为是许多癌症的预后因素,较高的相对表达表现为肿瘤进展的标志[1]。

CD74 (HLA class II histocompatibility antigen gamma chain; HLA-DR antigens-associated invariant chain) is a type II transmembrane protein. CD74 is involved in the formation and transport of MHC class II peptide complexes for the generation of CD4+ T cell responses. Cell surface CD74 serves as a receptor for the cytokine, macrophage migration inhibitory factor (MIF) on many cell types. In immune cells, MIF binding to CD74 induces a signaling cascade that results in regulation of cell proliferation and survival. CD74 has been associated with tumor progression and metastasis. CD74 expression has been suggested to serve as a prognostic factor in many cancers, with higher relative expression behaving as a marker of tumor progression[1].

共 1种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
PADRE peptide

PADRE peptide 是一种泛 HLA-DR 结合表位和免疫刺激剂,能够结合 MHC II 类分子的肽结合槽以呈递给 CD4+ T 细胞,从而有效刺激特异性免疫反应;它不仅能增强抗肿瘤免疫应答、抑制肿瘤生长并延长生存期,还能在与基于 E7 肽的疫苗及 poly(I:C) 联合使用时显著提升 E7 特异性 CD8+ T 细胞的频率及针对 TC-1 肿瘤的疗效,但其诱导的免疫应答强度不及 Ii-PADRE DNA 疫苗,且无法增强 CRT-E7 DNA 的免疫效果,因此可广泛应用于黑色素瘤、胶质母细胞瘤及宫颈癌等相关肿瘤的研究。

161147-59-7
Ligand
98.28%
PADRE peptide

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础